Tesamorelin: The Peptide That Targets Visceral Fat

Not all body fat is created equal. The soft fat you can pinch under your skin is mostly harmless. The fat you can't pinch, the deep abdominal fat wrapped around your organs, is the one quietly driving heart disease, insulin resistance, and inflammation.

That deep fat is called visceral fat, and it's notoriously stubborn. Diet and exercise help, but many people hit a wall where the belly simply won't budge no matter how disciplined they are. Tesamorelin is one of the few tools with real clinical data behind its ability to target exactly that.

Here's an honest look at what it does, who it's actually approved for, and where the science stands.

What tesamorelin is

Tesamorelin is a synthetic version of a natural signal your body already makes: growth hormone-releasing hormone, or GHRH. It's a peptide, meaning a short chain of amino acids, and it works on the growth hormone system in a specific and rather elegant way.

Rather than injecting growth hormone directly into your body, tesamorelin prompts your own pituitary gland to release growth hormone in its natural, pulsatile rhythm. This is an important distinction. It's the difference between replacing a hormone and stimulating your body to produce its own.

Stimulation, not replacement (why this matters)

When you take growth hormone directly, you override your body's own regulatory system. Tesamorelin does the opposite. It restores the natural conversation between your hypothalamus and pituitary gland, encouraging your body to release growth hormone the way it would on its own, in pulses, respecting the natural feedback loops that keep the system in balance.

That "physiologic" approach is a big part of why tesamorelin has become one of the more respected peptides in metabolic medicine. It's working with your biology, not steamrolling it.

The main event: visceral fat reduction

This is what tesamorelin is known for, and the evidence here is genuinely strong.

In the pooled Phase III clinical trials that led to its approval, tesamorelin reduced visceral adipose tissue by roughly 15% compared to placebo over 26 weeks, alongside reductions in fasting triglycerides. Those are real, reproducible, well-documented results, not marketing estimates.

What makes it stand out is its selectivity. Tesamorelin preferentially reduces the deep visceral fat while largely sparing the subcutaneous fat just under your skin. In a world of treatments that cause generalized weight loss, a tool that specifically targets the metabolically dangerous fat is a different kind of instrument, more scalpel than sledgehammer.

And because visceral fat is so tightly linked to cardiovascular risk, insulin resistance, and chronic inflammation, reducing it isn't a cosmetic win. It's a metabolic one.

The liver connection

Deep abdominal fat and fatty liver tend to travel together, and this is where some of the most interesting research on tesamorelin has emerged.

In a randomized, double-blind, multicenter trial, tesamorelin taken daily for 12 months reduced liver fat and helped prevent the progression of liver fibrosis (scarring), while also lowering markers of hepatic inflammation. A more recent randomized trial reported meaningful drops in both visceral fat and hepatic fat fraction. Earlier studies had already shown reductions in liver fat and improvements in liver enzymes.

Taken together, these findings suggest tesamorelin's benefits to the liver may end up being just as clinically important as its effects on the waistline, though, as with everything here, the strongest data comes from a specific population (more on that next).

The honest part: who it's actually approved for

This is the context that separates responsible information from hype.

Tesamorelin (brand names Egrifta SV and, as of a March 2025 FDA approval, the easier-to-administer Egrifta WR) is FDA-approved for one specific purpose: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That's the population every one of the major clinical trials studied.

That matters because it means:

• Its use for general (non-HIV) visceral fat, fatty liver, body composition, or "anti-aging" is off-label. The mechanism is the same, and the early data outside the HIV population is encouraging, but the large, gold-standard trials were conducted in people with HIV. Honest providers acknowledge that distinction rather than blurring it.

• It is not a weight-loss drug, and it is not a GLP-1 like semaglutide (Ozempic/Wegovy). It doesn't work by suppressing appetite, and it shouldn't be thought of as a substitute for those medications or as a general obesity treatment. It targets a specific type of fat, not the number on the scale.

  
  

What treatment actually involves

Tesamorelin is a daily subcutaneous injection, typically into the abdomen, with injection sites rotated to protect the tissue. It's a prescription medication that calls for proper medical oversight, including baseline lab work and ongoing monitoring, because it can affect blood sugar (there's a risk of raising glucose levels) and because growth hormone activity is measured through a marker called IGF-1.

It isn't appropriate for everyone. It's contraindicated in pregnancy, in people with active cancer, and in those with certain pituitary conditions, among others. This is precisely why it belongs in the hands of a provider who evaluates your candidacy and monitors you over time, not something to approach casually.

The bottom line

Tesamorelin is one of the more scientifically grounded peptides available. It has FDA approval, Phase III trial data, and a mechanism that respects your body's own hormonal rhythm rather than overriding it. Its ability to selectively target visceral fat, and its promising effects on liver fat, make it a genuinely interesting tool for the right person.

But "the right person" is the key phrase. Its proven evidence lives in a specific population, its use beyond that is off-label, and it's a precision metabolic tool rather than a weight-loss shortcut. Used thoughtfully, with proper evaluation and monitoring, it can be a powerful part of a metabolic-health strategy. Used carelessly, or oversold as a miracle, it's neither.

If your deep abdominal fat hasn't responded to diet and exercise and you're curious whether tesamorelin fits your situation, the right next step is a real conversation with a provider who knows both the science and the caveats.

Currently treating patients located in:

Colorado, Florida, Hawaii, and Washington!

Click the link to schedule a consultation today!

https://mana-loa.clientsecure.me

-The Mana Loa Health Team

Patient safety is Mana Loa Health's top priority. The information discussed on this blog is not intended to recommend the self management of health problems or wellness. It is not intended to endorse or recommend any particular type of medical treatment or advice. The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please talk to your healthcare provider. No information contained on this blog should be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider.

References

• Falutz J, et al. Phase III trials of tesamorelin for visceral fat reduction in HIV-associated lipodystrophy (pooled analysis; ~15% visceral fat reduction at 26 weeks). Summarized at: https://superpower.com/guides/tesamorelin

• Stanley TL, et al. "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial." The Lancet HIV. 2019. https://pubmed.ncbi.nlm.nih.gov/31655701/

• Russo GT, Ockene M, et al. Randomized placebo-controlled trial of tesamorelin in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD). AIDS. 2024.

• U.S. FDA approval of EGRIFTA WR (reformulated tesamorelin), March 2025.